BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol 2015;8:119-30. [PMID: 25897254 DOI: 10.2147/CEG.S48305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheung AC, Lazaridis KN, LaRusso NF, Gores GJ. Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol 2017;33:149-57. [PMID: 28257308 DOI: 10.1097/MOG.0000000000000352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
2 Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. J Crohns Colitis. 2018;12:S641-S652. [PMID: 30137309 DOI: 10.1093/ecco-jcc/jjx145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
3 Pathak M, Lal G. The Regulatory Function of CCR9+ Dendritic Cells in Inflammation and Autoimmunity. Front Immunol 2020;11:536326. [PMID: 33123124 DOI: 10.3389/fimmu.2020.536326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Rehman A, Baloch NU, Morrow JP, Pacher P, Haskó G. Targeting of G-protein coupled receptors in sepsis. Pharmacol Ther 2020;211:107529. [PMID: 32197794 DOI: 10.1016/j.pharmthera.2020.107529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Rivera-nieves J. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments. Current Opinion in Gastroenterology 2015;31:441-8. [DOI: 10.1097/mog.0000000000000218] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
6 Hegazy AN, West NR, Stubbington MJT, Wendt E, Suijker KIM, Datsi A, This S, Danne C, Campion S, Duncan SH, Owens BMJ, Uhlig HH, McMichael A;  Oxford IBD Cohort Investigators; Bergthaler A, Teichmann SA, Keshav S, Powrie F. Circulating and Tissue-Resident CD4+ T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation. Gastroenterology 2017; 153: 1320-1337. e16. [PMID: 28782508 DOI: 10.1053/j.gastro.2017.07.047] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 25.4] [Reference Citation Analysis]
7 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis 2019;25:270-82. [PMID: 30165490 DOI: 10.1093/ibd/izy269] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
8 Wold EA, Chen J, Cunningham KA, Zhou J. Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. J Med Chem 2019;62:88-127. [PMID: 30106578 DOI: 10.1021/acs.jmedchem.8b00875] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
9 Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol 2021. [PMID: 34316007 DOI: 10.1038/s41385-021-00433-3] [Reference Citation Analysis]
10 Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol 2016;9:59-70. [PMID: 27042137 DOI: 10.2147/CEG.S53381] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
11 Arimont M, Sun SL, Leurs R, Smit M, de Esch IJP, de Graaf C. Structural Analysis of Chemokine Receptor-Ligand Interactions. J Med Chem 2017;60:4735-79. [PMID: 28165741 DOI: 10.1021/acs.jmedchem.6b01309] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 11.4] [Reference Citation Analysis]
12 Oswald C, Rappas M, Kean J, Doré AS, Errey JC, Bennett K, Deflorian F, Christopher JA, Jazayeri A, Mason JS, Congreve M, Cooke RM, Marshall FH. Intracellular allosteric antagonism of the CCR9 receptor. Nature 2016;540:462-5. [PMID: 27926729 DOI: 10.1038/nature20606] [Cited by in Crossref: 130] [Cited by in F6Publishing: 120] [Article Influence: 21.7] [Reference Citation Analysis]
13 Chaturvedi M, Schilling J, Beautrait A, Bouvier M, Benovic JL, Shukla AK. Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. Trends Biochem Sci 2018;43:533-46. [PMID: 29735399 DOI: 10.1016/j.tibs.2018.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
14 Lynch KD, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Curr Hepatol Rep. 2019;18:115-126. [PMID: 31008013 DOI: 10.1007/s11901-019-00456-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]